Frontiers in Oncology (Mar 2022)
The Evolution of Clinicopathological Diagnostic Features of Upper Tract Urothelial Carcinoma in China: A Summary of 2561 Cases in the Last 20 Years
- Chunru Xu,
- Chunru Xu,
- Chunru Xu,
- Changwei Yuan,
- Changwei Yuan,
- Changwei Yuan,
- Cuijian Zhang,
- Cuijian Zhang,
- Cuijian Zhang,
- Dong Fang,
- Dong Fang,
- Dong Fang,
- Yanfei Yu,
- Yanfei Yu,
- Yanfei Yu,
- Xiang Wang,
- Xiang Wang,
- Xiang Wang,
- Zhihua Li,
- Zhihua Li,
- Zhihua Li,
- Zhihua Li,
- Yan Wang,
- Yan Wang,
- Yan Wang,
- Yan Wang,
- Qi Tang,
- Qi Tang,
- Qi Tang,
- Gengyan Xiong,
- Gengyan Xiong,
- Gengyan Xiong,
- Lei Zhang,
- Lei Zhang,
- Lei Zhang,
- Zhisong He,
- Zhisong He,
- Zhisong He,
- Jian Lin,
- Jian Lin,
- Jian Lin,
- Liqun Zhou,
- Liqun Zhou,
- Liqun Zhou,
- Xuesong Li,
- Xuesong Li,
- Xuesong Li
Affiliations
- Chunru Xu
- Department of Urology, Peking University First Hospital, Beijing, China
- Chunru Xu
- Institute of Urology, Peking University, Beijing, China
- Chunru Xu
- National Urological Cancer Center, Beijing, China
- Changwei Yuan
- Department of Urology, Peking University First Hospital, Beijing, China
- Changwei Yuan
- Institute of Urology, Peking University, Beijing, China
- Changwei Yuan
- National Urological Cancer Center, Beijing, China
- Cuijian Zhang
- Department of Urology, Peking University First Hospital, Beijing, China
- Cuijian Zhang
- Institute of Urology, Peking University, Beijing, China
- Cuijian Zhang
- National Urological Cancer Center, Beijing, China
- Dong Fang
- Department of Urology, Peking University First Hospital, Beijing, China
- Dong Fang
- Institute of Urology, Peking University, Beijing, China
- Dong Fang
- National Urological Cancer Center, Beijing, China
- Yanfei Yu
- Department of Urology, Peking University First Hospital, Beijing, China
- Yanfei Yu
- Institute of Urology, Peking University, Beijing, China
- Yanfei Yu
- National Urological Cancer Center, Beijing, China
- Xiang Wang
- Department of Urology, Peking University First Hospital, Beijing, China
- Xiang Wang
- Institute of Urology, Peking University, Beijing, China
- Xiang Wang
- National Urological Cancer Center, Beijing, China
- Zhihua Li
- Department of Urology, Peking University First Hospital, Beijing, China
- Zhihua Li
- Institute of Urology, Peking University, Beijing, China
- Zhihua Li
- National Urological Cancer Center, Beijing, China
- Zhihua Li
- Department of Nursing, Peking University First Hospital, Beijing, China
- Yan Wang
- Department of Urology, Peking University First Hospital, Beijing, China
- Yan Wang
- Institute of Urology, Peking University, Beijing, China
- Yan Wang
- National Urological Cancer Center, Beijing, China
- Yan Wang
- Department of Nursing, Peking University First Hospital, Beijing, China
- Qi Tang
- Department of Urology, Peking University First Hospital, Beijing, China
- Qi Tang
- Institute of Urology, Peking University, Beijing, China
- Qi Tang
- National Urological Cancer Center, Beijing, China
- Gengyan Xiong
- Department of Urology, Peking University First Hospital, Beijing, China
- Gengyan Xiong
- Institute of Urology, Peking University, Beijing, China
- Gengyan Xiong
- National Urological Cancer Center, Beijing, China
- Lei Zhang
- Department of Urology, Peking University First Hospital, Beijing, China
- Lei Zhang
- Institute of Urology, Peking University, Beijing, China
- Lei Zhang
- National Urological Cancer Center, Beijing, China
- Zhisong He
- Department of Urology, Peking University First Hospital, Beijing, China
- Zhisong He
- Institute of Urology, Peking University, Beijing, China
- Zhisong He
- National Urological Cancer Center, Beijing, China
- Jian Lin
- Department of Urology, Peking University First Hospital, Beijing, China
- Jian Lin
- Institute of Urology, Peking University, Beijing, China
- Jian Lin
- National Urological Cancer Center, Beijing, China
- Liqun Zhou
- Department of Urology, Peking University First Hospital, Beijing, China
- Liqun Zhou
- Institute of Urology, Peking University, Beijing, China
- Liqun Zhou
- National Urological Cancer Center, Beijing, China
- Xuesong Li
- Department of Urology, Peking University First Hospital, Beijing, China
- Xuesong Li
- Institute of Urology, Peking University, Beijing, China
- Xuesong Li
- National Urological Cancer Center, Beijing, China
- DOI
- https://doi.org/10.3389/fonc.2022.769252
- Journal volume & issue
-
Vol. 12
Abstract
ObjectivesTo summarize the clinicopathological diagnostic features and evolutionary trends of upper tract urothelial carcinoma (UTUC) in China over the past 20 years.MethodsAll patients diagnosed with upper tract urothelial carcinoma in the Peking University First Hospital from 2001 to 2020 were retrospectively collected. Data were divided into two groups (2001-2010 and 2011-2020) according to the date of diagnosis. Statistical analysis was done with the SPSS V22.0. Chi-square analysis and t-test were adopted to analyze depending on the data type. Subgroup analysis based on 5 years was used for visualization to present trends. Both Kaplan-Meier curve and Cox regression were used for univariate and multivariate survival analysis.ResultsThe study included 2561 cases diagnosed with upper tract urothelial carcinoma in total. Compared with the first decade (2001-2010), patients of the second decades (2011-2020) had elder mean age (66.65 versus 67.59, years, p=0.025), higher male proportion (43.5% versus 49.0%, p=0.034), lower incidence of renal pelvic tumors (53.4% versus 45.8%, p<0.001) and multifocality (18.6% versus 12.0%, p<0.001), higher incidence of ureteral tumors (52.2% versus 60.9%, p<0.001).In recent ten years, the incidence of muscle-invasive urothelial carcinoma (pT2+) decreased significantly (64.4% versus 54.9%, p<0.001),and the mean size of renal pelvic tumors increased(3.46 versus 3.73, cm, p=0.043). The size of the ureteral tumor, the histopathologic grade showed no significant change. The prognostic analysis based on 709 patients regularly followed at our center revealed that the male gender and G3 histopathological grade were independent risk factors for poorer prognosis in patients with UTUC.ConclusionIn the past 20 years, the clinicopathological diagnostic features of upper tract urothelial carcinoma in the Chinese population has changed significantly, suggesting an increased risk of a poorer prognosis for UTUC. This trend may be related to updating diagnostic techniques and self-monitoring awareness. However, we need more high-grade, multicenter trials to verify it in the future.
Keywords
- evolution
- clinicopathological diagnostic features
- upper tract urothelial carcinoma (UTUC)
- Chinese population
- 20 years